Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.46 |
| ▸ | PTN | P21246 | 2/20 | 0.46 |
| ▸ | MDK | P21741 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.33 |
| ▸ | MAG | P20916 | 2/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.31 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695250 | 0.86 | MAPK1 (0.50) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL24530053 | 0.80 | MAPK1 (0.47) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL26471213 | 0.79 | BDNF (0.44) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL18098580 | 0.79 | ALDH1A1 (0.47) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL21650603 | 0.79 | ALDH1A1 (0.47) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL19509535 | 0.78 | MAPK1 (0.46) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL23251210 | 0.78 | BDNF (0.46) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL23135897 | 0.78 | BDNF (0.53) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL19546052 | 0.78 | MAPK1 (0.47) | BDNFPTNMDKMAPK1LGALS3 | |
| SCHEMBL20235169 | 0.77 | MAPK1 (0.49) | BDNFPTNMDKMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111375-B2 | Compositions and methods for generating oligodendrocyte precursors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-07 | — | — | US | disclosed |
| US-10982055-B2 | Thermoreversible polymers and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111375-B2 | Compositions and methods for generating oligodendrocyte precursors | PMP22, GMFG, MAG | BDNF 19/4885PTN 574/4885MDK 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.